자궁경부암 진단 시장 규모, 점유율 및 동향 분석 보고서 : 검사 유형별, 연령대별, 최종 용도별, 지역별, 부문별 예측(2023-2030년)

Cervical Cancer Diagnostic Market Growth & Trends:

The global cervical cancer diagnostic market size is expected to reach USD 7.0 billion by 2030, growing at a CAGR of 5.7% from 2023 to 2030, according to a new study conducted by Grand View Research, Inc.. The key driving factors include the rising prevalence of cervical cancer, evolving screening technology, and various programs that promote routine check up and screening. According to the data published by the WHO, in 2012, over 270,000 women died due to cervical cancer, majority of which were from the developing countries. It is one of the most common cancer type diagnosed in women. Some of the etiological factors are multiple sex partners, and changing lifestyle, such as drinking & smoking and increased stress levels.

Furthermore, favorable government initiatives and increasing number of awareness programs are further expected to promote the market growth in coming few years. The National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, are working towards promoting the necessity for early screening of cervical cancer amongst mid aged women.

There is an increasing demand for technologically advanced diagnostic procedures that facilitate the early intervention of the disease. The industry players are focused on developing innovative technological solutions for accurate and efficient results. Advancement in screening techniques, such as use of biomarkers, is gaining importance. The upsurge in technological developments is anticipated to further drive industry growth.

On account of increasing adoption of Pap test, the number of deaths due to cervical cancer has declined significantly in past few years. It helps detect precancerous lesions at an early state and, thus, reduces the number of cervical cancer cases. The American Cancer Society stated that the cervical cancer cases in last 40 years in the U.S. have declined by more than 50%. Initially, the Pap test screening was carried out every year which lead to further unnecessary procedures. However, the American Cancer Society now recommends that women in the age group of 21 to 29 should undergo Pap test every 3 years.

Cervical Cancer Diagnostic Market Report Highlights:

• In 2022, the Pap testing segment held majority of the market share of 33.06%. The segment's large share can be attributed to the high efficiency of the tests in early diagnosis. Also, the increasing awareness about the impact of early diagnosis contributed to its growth.
• In 2022, North America was the leading regional market with a revenue share of 45.74%. The U.S. is a key market in North America. Growing incidence of cervical cancer coupled with initiatives undertaken by government agencies in the form of awareness programs pertaining to the early screening of the disease are key factors for the country's large market share.
• Asia Pacific is expected to witness lucrative growth over the forecast period growing at a CAGR of 8.6%. The various steps undertaken by governments of developing countries such as India, China, Philippines, and other in order to improve healthcare infrastructure and to improve access to healthcare facilities are amongst key factors attributing to region's high growth. Also, high prevalence of cancer in developing nations and increasing consumer awareness levels drive the growth
• This market is presently dominated by a few key participants such as Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Abbott Laboratories, OncoHealth Corp, Hologic, Inc., QIAGEN, Quest Diagnostics, Inc and Guided Therapeutics, Inc. The key players focus specially on developing innovative solutions for diagnosis. For instance, F. Hoffmann-La Roche Ltd., in 2014, launched automated CINtec PLUS cytology test that efficiently detects the presence of precancerous cells.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Test Type
  • 1.1.2. Age group
  • 1.1.3. End use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Test Type outlook
  • 2.2.2. Age group outlook
  • 2.2.3. End use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Cervical Cancer Diagnostic Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Industry Value Chain Analysis
  • 3.3.1. Reimbursement framework
• 3.4. Market Dynamics
  • 3.4.1. Market driver analysis
    • 3.4.1.1. The increasing demand for cervical cancer screening tools
    • 3.4.1.2. Increase in cervical cancer cases across the globe
    • 3.4.1.3. Technological advancements
  • 3.4.2. Market restraint analysis
    • 3.4.2.1. Limited number of approved products
    • 3.4.2.2. Complications/risks associated with microneedles
• 3.5. Cervical Cancer Diagnostic Market Analysis Tools
  • 3.5.1. Industry Analysis - Porter's
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis
    • 3.5.2.1. Political landscape
    • 3.5.2.2. Technological landscape
    • 3.5.2.3. Economic landscape
  • 3.5.3. Major Deals & Strategic Alliances Analysis
  • 3.5.4. Market Entry Strategies

Chapter 4. Cervical Cancer Diagnostic Market: Test Type Estimates & Trend Analysis

• 4.1. Cervical Cancer Diagnostic Market, By Test Type Key Takeaways
• 4.2. Cervical Cancer Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Pap Testing
  • 4.3.1. Pap testing market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. HPV Testing
  • 4.4.1. HPV testing market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Colposcopy
  • 4.5.1. Colposcopy market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Cervical Biopsies
  • 4.6.1. Cervical biopsies market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.7. Cystoscopy
  • 4.7.1. Cystoscopy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Cervical Cancer Diagnostic market: Age group Estimates & Trend Analysis

• 5.1. Cervical Cancer Diagnostic Market, By Age group Key Takeaways
• 5.2. Cervical Cancer Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. 20-40 years
  • 5.3.1. 20-40 years market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Above 40 years
  • 5.4.1. Above 40 years market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Cervical Cancer Diagnostic market: End Use Estimates & Trend Analysis

• 6.1. Cervical Cancer Diagnostic Market, By End Use Key Takeaways
• 6.2. Cervical Cancer Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
• 6.3. Hospitals
  • 6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Laboratories
  • 6.4.1. Laboratories market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Diagnostic Centers
  • 6.5.1. Diagnostic centers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Cervical Cancer Diagnostic Market: Regional Estimates & Trend Analysis

• 7.1. Regional Outlook
• 7.2. Cervical Cancer Diagnostic Market by Region: Key Marketplace Takeaway
• 7.3. North America
  • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.3. France
    • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.6. Sweden
    • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.7. Norway
    • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.2. China
    • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.3. India
    • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.5. Thailand
    • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.2. Mexico
    • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.7. MEA
  • 7.7.1. Saudi Arabia
    • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
  • 8.2.1. Abbott Laboratories
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Product benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. Ouigan NV
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Product benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Thermo Fisher Scientific Inc
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Dickinson and Company
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Hologic Inc
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. CooperSurgical Inc
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. Siemens Healthineers
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives